Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 6/20 | 0.35 |
| ▸ | ACACA | Q13085 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 3/20 | 0.31 |
| ▸ | TP53 | P04637 | 2/20 | 0.31 |
| ▸ | DRD2 | P14416 | 2/20 | 0.31 |
| ▸ | HTR2A | P28223 | 2/20 | 0.31 |
| ▸ | HTR2C | P28335 | 2/20 | 0.31 |
| ▸ | DRD3 | P35462 | 2/20 | 0.31 |
| ▸ | HTR6 | P50406 | 2/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6113569 | 0.86 | CNR2 (0.35) | ACACBACACADRD2HTR2AHTR2C | |
| SCHEMBL6114040 | 0.82 | SMN1; SMN2 (0.42) | MAPTTP53MAPK1RAB9ASMN1; SMN2 | |
| SCHEMBL14335649 | 0.82 | DPP4 (0.34) | KDM4EPOLBMAPTDRD2DRD3 | |
| SCHEMBL2362821 | 0.77 | KDM4E (0.36) | ACACBACACAKDM4EPOLBDRD2 | |
| SCHEMBL14405317 | 0.77 | — | — | |
| SCHEMBL2759720 | 0.77 | ACACB (0.42) | ACACBACACABRD4 | |
| SCHEMBL2362432 | 0.77 | ACACB (0.34) | ACACBACACAMAPTTP53BRD4 | |
| SCHEMBL14335924 | 0.75 | USP2 (0.31) | — | |
| SCHEMBL2362127 | 0.73 | ACACB (0.35) | ACACBACACABRD4SMN1; SMN2 | |
| SCHEMBL2363015 | 0.72 | ALDH1A1 (0.39) | POLBMAPTTP53MEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2723723-B1 | N-OXY PYRAZOLO-TRIAZEPINE-DIONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2017-02-01 | — | — | EP | disclosed |
| US-9282743-B2 | Chemical compounds | SYNGENTA PARTICIPATIONS AG (CH) | 2016-03-15 | — | — | US | disclosed |
| US-20140148339-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-05-29 | — | — | US | disclosed |
| US-20140148339-A1 | CHEMICAL COMPOUNDS | SYNGENTA PARTICIPATIONS AG (CH) | 2014-05-29 | — | — | US | disclosed |
| WO-2012175666-A1 | N-OXY PYRAZOLO-TRIAZEPINE-DIONE DERIVATIVES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140148339-A1 | CHEMICAL COMPOUNDS | DDT, CYP1B1, CYP1A1 | ACACB 389/4885ACACA 311/4885KDM4E 1437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.